Hepatitis C virus particle assembly involves phosphorylation of NS5A by the c-Abl tyrosine kinase by Yamauchi, Shota et al.
Tyrosine Phosphorylation of HCV NS5A 
 1 
Hepatitis C Virus Particle Assembly Involves Phosphorylation of NS5A by the c-Abl Tyrosine Kinase 
 
Shota Yamauchi1,3, Kenji Takeuchi1,3, Kazuyasu Chihara1,3, Xuedong Sun1, Chisato Honjoh1,2, 
Hatsumi Yoshiki1, Hak Hotta4, and Kiyonao Sada1,3* 
 
From the 1Division of Genome Science and Microbiology, Department of Pathological Sciences, and the 
2Third Department of Internal Medicine, Faculty of Medical Sciences, and the 3Organization for Life 
Science Advancement Programs, University of Fukui, Fukui 910-1193, Japan 
 
4 Division of Microbiology, Kobe University Graduate School of Medicine, Kobe 650-0017, Japan 
 
*Running title: Tyrosine Phosphorylation of HCV NS5A 
 
To whom correspondence should be addressed: Kiyonao Sada, Division of Genome Science and 
Microbiology, Department of Pathological Sciences, Faculty of Medical Sciences, University of Fukui, 
23-3 Matsuoka-Shimoaizuki, Eiheiji, Fukui 910-1193, Japan. Tel.: 81-776-61-8323; Fax: 
81-776-61-8104; E-mail: ksada@u-fukui.ac.jp   
 
Keywords: ABL tyrosine kinase; hepatitis C virus; host-pathogen interaction; virology; virus assembly                          
 
Background: HCV NS5A regulates viral RNA 
replication and virus particle assembly. 
Results: Phosphorylation of NS5A by c-Abl is 
required for efficient production of infectious 
HCV particles but not for viral RNA replication. 
Conclusion: HCV particle assembly involves 
tyrosine phosphorylation of NS5A. 
Significance: This study provides the first 
evidence for the importance of NS5A tyrosine 
phosphorylation in the HCV life cycle. 
 
ABSTRACT  
 Hepatitis C virus (HCV) nonstructural 
protein 5A (NS5A) is thought to regulate the 
replication of viral RNA and the assembly of virus 
particles in a serine/threonine 
phosphorylation-dependent manner. However, the 
host kinases that phosphorylate NS5A are not fully 
identified. Here, we show that HCV particle 
assembly involves phosphorylation of NS5A by 
the c-Abl tyrosine kinase. Pharmacological 
inhibition or knockdown of c-Abl reduces the 
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production of infectious HCV (J6/JFH1) particles 
in Huh-7.5 cells, without markedly affecting viral 
RNA translation and replication. NS5A is 
tyrosine-phosphorylated in HCV-infected cells, 
and this phosphorylation is also reduced by 
knockdown of c-Abl. Mutational analysis reveals 
that NS5A tyrosine phosphorylation is dependent, 
at least in part, on Tyr330 (Tyr2306 in polyprotein 
numbering). Mutation of this residue to 
phenylalanine reduces the production of infectious 
HCV particles, but does not affect the replication 
of the JFH1 subgenomic replicon. These findings 
suggest that c-Abl promotes HCV particle 
assembly by phosphorylating NS5A at Tyr330. 
 
 Hepatitis C virus (HCV) is an 
enveloped, positive-strand RNA virus of the 
family Flaviviridae (1-3). Following entry into the 
host cell, the RNA genome of HCV is translated 
into a polyprotein of ~3,000 amino acids. The 
polyprotein is co- and post-translationally cleaved 
by viral and host proteases to yield three structural 
(core, E1, and E2) and seven nonstructural (p7, 
NS2, NS3, NS4A, NS4B, NS5A, and NS5B) 
proteins. By definition, the structural proteins are 
incorporated into virus particles. The nonstructural 
proteins, on the other hand, form RNA replication 
complexes on ER-derived membranous 
compartments (4). Many of the nonstructural 
proteins also facilitate the assembly of virus 
particles. 
 Recent evidence suggests that HCV 
particle assembly is initiated near the interface 
between the ER membrane and cytosolic lipid 
droplets (LDs), organelles for the storage of 
neutral lipids (5-7). After proteolytic maturation at 
the ER membrane, the capsid protein core traffics 
to the surface of LDs (8), where it binds to viral 
RNA. The resulting nucleocapsids acquire 
envelopes by budding into the ER lumen and 
mature into virus particles. The virus particles are 
released from the host cell through the secretory 
pathway.  
 NS5A is a non-enzymatic protein that 
plays a critical but as yet undefined role in RNA 
replication and particle assembly (9). NS5A 
consists of an amino-terminal amphipathic α-helix 
and three structural domains (domains I-III). The 
amphipathic α-helix anchors NS5A to the 
cytosolic side of the ER membrane (10, 11). 
Domains I and II are required at least for RNA 
replication (12, 13), whereas domain III is 
required for particle assembly (14). NS5A binds to 
viral RNA in vitro (15, 16) and has therefore been 
proposed to transport viral RNA from replication 
complexes to LD-resident core (6, 7). 
 NS5A is a phosphoprotein that exists in 
basally phosphorylated (p56) and 
hyperphosphorylated (p58) forms (17, 18). Studies 
using HCV subgenomic replicons have proposed 
that NS5A hyperphosphoyrlation negatively 
regulates RNA replication (19-21). Although 
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multiple serine and threonine phosphorylation 
sites have been identified in NS5A (21, 22), their 
roles in particle assembly are unknown, except for 
a serine residue at the carboxy terminus of domain 
III. This residue, Ser457, is phosphorylated by 
casein kinase (CK) II in vitro (23) and is required 
for efficient particle assembly (23, 24). A recent 
study has shown that CK I is also involved in 
HCV particle assembly through NS5A 
hyperphosphorylation (25). In addition to serine 
and threonine phosphorylation, we have reported 
that overexpressed NS5A is 
tyrosine-phosphorylated in response to treatment 
with pervanadate, an inhibitor of protein tyrosine 
phosphatases (26). Moreover, we and others have 
reported that NS5A binds to non-receptor protein 
tyrosine kinases such as c-Src, Fyn, Syk, and 
c-Abl in vitro (26-28). However, whether NS5A is 
tyrosine-phosphorylated in HCV-infected cells is 
yet to be determined.  
 The c-Abl tyrosine kinase was 
discovered as the cellular homolog of v-Abl, the 
oncoprotein of the Abelson murine leukemia virus 
(29), and has since been implicated in human 
cancers (30). In patients with chronic myeloid 
leukemia (CML), the gene for c-Abl has been 
translocated from chromosome 9 to chromosome 
22 (31). The derivative chromosome 22, known as 
the Philadelphia chromosome, directs the 
expression of the fusion protein Bcr-Abl, the cause 
of CML. The Abl family kinase inhibitor imatinib 
has proved effective and well tolerated in the 
treatment of CML and is considered a paradigm of 
targeted therapeutics.  
 The Abl family of non-receptor tyrosine 
kinases consists of c-Abl and Arg (30). Viruses 
such as coxsackie B virus (32), vaccinia virus (33), 
and Ebola virus (34) exploit c-Abl and Arg for 
their entry or egress (35). Although imatinib has 
been identified as a potential anti-HCV agent in an 
unbiased compound screen (36), the role of Abl 
family kinases in the HCV life cycle is unknown. 
 In this study, we show that c-Abl is 
involved in HCV particle assembly. We also show 
that c-Abl phosphorylates NS5A at Tyr330 both in 
vitro and in the context of HCV infection and that 
this residue is required for efficient particle 
assembly. Our results suggest that c-Abl promotes 




 Cell Culture—Huh-7.5 human 
hepatoma cells were kindly provided by Charles 
M. Rice (The Rockefeller University) and were 
cultured in DMEM (Wako) supplemented with 
10% FBS (Sigma-Aldrich) and 0.1 mM 
nonessential amino acids (Wako). COS-7 cells and 
HEK293T cells were cultured in DMEM 
supplemented with 10% FBS. Transfection was 
performed using FuGENE6 (Promega). 
 Antibodies and Reagents—Anti-core 
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(C7-50) antibody was purchased from Abcam. 
Anti-c-Abl (8E9) antibody was purchased from 
BD Pharmingen. Anti-Arg, anti-Myc (9E10), and 
anti-c-Abl antibodies were purchased from Santa 
Cruz Biotechnology. Anti-GAPDH (6C5) and 
anti-phosphotyrosine (4G10) antibodies were 
purchased from Merck Millipore. Anti-GST (5A7) 
antibody was purchased from Wako. Anti-Flag 
antibody was purchased from MBL. Anti-Flag 
(M2) antibody was purchased from Sigma-Aldrich. 
Anti-NS5A (9E10) antibody was kindly provided 
by Charles M. Rice (37). Imatinib mesylate was 
purchased from Wako. 
 Plasmids—To produce retroviruses 
encoding shRNAs against human c-Abl and Arg, 
the c-Abl target sequence, 
5´-GAGTTCTTGAAGCATTTCAAA-3´, and Arg 
target sequence, 
5´-GCTGGAATGTGCTGACCTACT-3´, were 
cloned into pSuper retro-puro and pSuper 
retro-hygro (Oligoengine), respectively (38). The 
sequences of human c-Abl and Arg were amplified 
by PCR from Huh-7.5 cell cDNAs and cloned into 
pcDNA3. pcDNA3-murine c-Abl and 
pcDNA3-murine c-Abl KD (K290M) were kindly 
provided by Tomoyuki Shishido (Nara Institute of 
Science and Technology). The sequence of murine 
c-Abl was amplified by PCR from 
pcDNA3-murine c-Abl and cloned into 
pcDNA3-Flag. pEF1A-NS5A (Con1)-Myc-His 
was described previously (28). Site-directed 
mutagenesis was used to replace conserved 
tyrosine residues in NS5A with phenylalanine. 
pFL-J6/JFH1 was kindly provided by Charles M. 
Rice (37). Site-directed mutagenesis was used to 
replace NS5A Tyr330 with phenylalanine. 
EcoRI/Bsp1407I and ClaI/Bsp1407I fragments 
were cloned into pFL-J6/JFH1 and pSGR-JFH1 
(39), respectively. pSGR-JFH1 was kindly 
provided by Takaji Wakita (National Institute of 
Infectious Diseases). The sequence of NS5A 
domain II (amino acids 250-338) was amplified by 
PCR from pFL-J6/JFH1 and cloned into 
pGEX-4T-3. 
 HCV Infection—HCVcc (J6/JFH1) with 
adaptive mutations (P-47) was described 
previously (40). Huh-7.5 cells were infected with 
HCVcc at a multiplicity of infection of 3. Media 
were replaced with fresh media 4-6 h after 
infection. 
 Focus-Forming Assay—To evaluate 
extracellular infectivity, culture supernatants were 
collected. To evaluate intracellular infectivity, 
cells were trypsinized and suspended in culture 
media. Cells were centrifuged at 2,000 × g for 2 
min, suspended in culture media, and subjected to 
three cycles of freezing and thawing. Samples 
were centrifuged at 2,000 × g for 2 min. 
Supernatants were used to infect naive Huh-7.5 
cells. Cells were incubated for 72 h, fixed with 
methanol for 20 min at –20°C, and stained with 
anti-core antibody. Foci of infected cells were 
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manually counted with a fluorescence microscope 
(IX70, Olympus).  
 Real-Time PCR—Cells were washed 
three times with PBS. Total RNA was extracted 
using a High Pure RNA isolation kit (Roche). One 
hundred ng of total RNA was subjected to reverse 
transcription. RNA in culture supernatants was 
extracted using a QIAamp Viral RNA Mini Kit 
(Qiagen). Real-time PCR was performed using a 
SYBR FAST qPCR kit (KAPA Biosystems) and a 
StepOne Plus real-time PCR system (Life 
Technologies). Reactions contained HCV-specific 
forward and reverse primers 
(5´-CTTCACGCAGAAAGCGTCTA-3´ and 
5´-CAAGCACCCTATCAGGCAGT-3´, 
respectively). The standard curve was constructed 
using HCV RNA transcribed in vitro. To quantify 
c-Abl and Arg mRNA levels, real-time PCR was 
performed with c-Abl-specific forward and reverse 
primers (5´-GGCTGGGTCCCAAGCAA-3´ and 
5´-ACACAGGCCCATGGTACCA-3´, 




respectively). The standard curves were 
constructed using c-Abl and Arg RNA transcribed 
in vitro. 
 Retroviral Infection—Retroviral 
packaging was performed using HEK293T cells. 
Retrovirus-containing culture supernatants were 
filtered through a 0.45-µm-pore-size filter and 
used to infect Huh-7.5 cells in the presence of 8 
µg/ml polybrene for 8 h. After fresh media were 
added, cells were incubated for 48 h. 
 Immunoblotting—Cells were lysed in 
lysis buffer (50 mM Tris [pH 7.4], 150 mM NaCl, 
10 mM EDTA, 100 mM NaF, 1 mM Na3VO4, 1% 
Triton X-100, 0.5% deoxycholate, 0.1% SDS, 1 
mM PMSF, 2 µg/ml aprotinin) and centrifuged at 
15,000 × g for 20 min at 4°C. 
Immunoprecipitation was performed using protein 
A Sepharose (GE Healthcare). Immunoprecipitates 
were subjected to SDS-PAGE. Blots were 
quantified using ImageJ software. 
 Purification of GST Fusion 
Proteins—Competent cells (DH5α) were 
transformed with pGEX-4T-3-NS5A domain II 
WT or Y330F and cultured in LB broth. The 
expression of the GST fusion proteins was induced 
by adding IPTG to a final concentration of 0.5 mM. 
LB cultures were incubated for 2 h at 37°C and 
centrifuged at 5,000 × g for 15 min at 4°C. After 
sonication in PBS containing 1 mM PMSF and 2 
µg/ml aprotinin, Triton X-100 was added to a final 
concentration of 1%. Lysates were cleared by 
centrifugation and incubated with glutathione 
Sepharose 4B (GE Healthcare) for 30 min at room 
temperature. GST fusion proteins were eluted with 
elution buffer (50 mM Tris [pH 8.0], 10 mM 
reduced glutathione).  
 In Vitro Kinase Assay—HEK293T cells 
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were transfected with pcDNA3-c-Abl-Flag, lysed 
in lysis buffer, and centrifuged at 15,000 × g for 
20 min. Immunoprecipitation was performed using 
anti-Flag antibody agarose (MBL). 
Immunoprecipitates were incubated with 
GST-NS5A domain II WT or Y330F in kinase 
buffer (20 mM Tris [pH 7.4], 1 mM DTT, 10 mM 
MgCl2, 10 mM ATP) for 15 min at room 
temperature and subjected to SDS-PAGE, 
followed by immunoblotting with 
anti-phosphotyrosine antibody.  
 In Vitro Transcription—In vitro 
transcription of HCV RNA was performed as 
described elsewhere (41). Briefly, DNA templates 
were linearized with XbaI and treated with mung 
bean nuclease. Linearized templates were treated 
with proteinase K and purified by 
ethanol-chloroform extraction. RNA was 
transcribed in vitro using a MEGAscript kit 
(Ambion) and purified using a High Pure RNA 
isolation kit. RNA stocks (1 µg/µl) were stored at 
–80°C. In vitro transcription of c-Abl and Arg 
RNA was performed similarly, except that 
linearized pcDNA3-c-Abl and pcDNA3-Arg were 
not treated with mung bean nuclease.   
 Electroporation—Cells were 
trypsinized, suspended in culture media, and 
centrifuged at 2,000 × g for 2 min. After washing 
with PBS, cells were suspended at 1×107 cells/ml 
in PBS. A cell suspension (400 µl) was mixed 
with 5 µg of RNA in a 4-µm gap cuvette and 
electroporated at 950 µF and 260 V using a Gene 
Pulser Xcell electroporation system (Bio-Rad). 
After a 10 min recovery time, cells were 
suspended in culture media and plated. 
 Immunofluorescence—Cells were fixed 
with 4% paraformaldehyde (PFA) for 30 min, 
permeabilized with 50 µg/ml digitonin for 5 min, 
and incubated with primary antibodies overnight at 
4°C. Alexa Fluor 488- and 555-conjugated 
anti-mouse IgG (Cell Signaling Technology) and 
Alexa Fluor 647-conjugated anti-rabbit IgG 
(Molecular Probes) were used as secondary 
antibodies. LDs were stained with 5 µg/ml 
BODIPY 493/503 (Molecular Probes). Nuclei 
were stained with Hoechst 33258 (Wako). Cells 
were observed with a confocal microscope (TCS 
SPII, Leica) equipped with a 100× oil-immersion 
objective. Acquired images were analyzed using 
ImageJ software. 
 IP-Real-Time PCR—IP-real-time PCR 
was performed as described elsewhere (24), with 
minor modifications. Cells were washed with PBS 
and incubated in hypotonic buffer (10 mM HEPES 
[pH 7.6], 1.5 mM MgCl2, 10 mM KCl, 1 mM 
PMSF) for 5 min on ice. NP-40 was added to a 
final concentration of 1%. Lysates were incubated 
for 10 min on ice and cleared by centrifuging at 
4,000 × g for 15 min. Glycerol was added to a 
final concentration of 5%. Lysates were precleared 
by incubating with protein A Sepharose for 30 min 
at room temperature and incubated with anti-Flag 
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or anti-core monoclonal antibody for 1h. 
Immunoprecipitation was performed using protein 
A Sepharose. Immunoprecipitates were washed 
three times with wash buffer (10 mM Tris [pH 7.6], 
100 mM KCl, 5 mM MgCl2, 1 mM DTT). 
Immunoprecipitated core was eluted by incubating 
with elution buffer (50 mM Tris [pH 8.0], 1% SDS, 
10 mM EDTA) for 10 min at 65°C. After 
incubation with 100 µg of proteinase K for 30 min 
at 37°C, coprecipitated HCV RNA was extracted 
using TRIzol LS reagent (Life Technologies) and 
subjected to reverse transcription and real-time 
PCR.   
 Statistical Analysis—Data were 
analyzed by unpaired Student’s t test. 
 
RESULTS 
 c-Abl Is Involved in HCV Particle 
Assembly—Treatment with the Abl inhibitor 
imatinib prevents spread of HCV infection in cell 
culture (36), but does not appear to affect virus 
entry (42). To determine which step in the HCV 
lifecycle is blocked by imatinib treatment, Huh-7.5 
cells were infected with cell culture-grown HCV 
(HCVcc) of the J6/JFH1 chimeric genome (37, 40) 
and were incubated in the presence or absence of 
imatinib. Extracellular and intracellular virus 
particles were harvested and quantified by 
focus-forming assay. Imatinib treatment markedly 
reduced both extracellular and intracellular 
infectivity (Fig. 1, A and B), while only marginally 
reducing intracellular HCV RNA levels (Fig. 1C) 
and core and NS5A expression (Fig. 1D). Imatinib 
treatment did not significantly affect cell viability 
(Fig. 1E), consistent with a previous study (36). 
These results indicate that imatinib treatment 
reduces HCV particle assembly with a minimal 
effect on viral RNA translation and replication. 
 Imatinib inhibits c-Abl, Arg, and 
several other tyrosine kinases (31, 43). To 
examine whether c-Abl or Arg is required for 
HCV particle assembly, Huh-7.5 cells stably 
expressing an shRNA against c-Abl or Arg, or 
both were established and infected with HCVcc. 
Knockdown of c-Abl and Arg was confirmed by 
immunoblotting (Fig. 2A). Similar to treatment 
with imatinib, knockdown of c-Abl reduced 
extracellular and intracellular infectivity (Fig. 2, B 
and C), but did not significantly affect intracellular 
HCV RNA levels (Fig. 2D) or core expression 
(Fig. 2E). These results indicate that c-Abl is 
involved in HCV particle assembly. In contrast, 
knockdown of Arg had no significant effect on 
extracellular or intracellular infectivity (Fig. 2, B 
and C). However, because Arg mRNA levels were 
more than 10 times lower than c-Abl mRNA levels 
in Huh-7.5 cells (Fig. 2F), the possibility cannot 
be excluded that Arg is also involved in HCV 
particle assembly.  
 c-Abl Phosphorylates NS5A at 
Tyr330—We have previously reported that the SH3 
domain of c-Abl binds to NS5A in vitro and that 
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overexpressed NS5A is tyrosine-phosphorylated in 
response to pervanadate treatment (26). We 
therefore investigated the possibility that c-Abl 
promotes HCV particle assembly by 
phosphorylating NS5A. NS5A was 
immunoprecipitated from lysates of 
HCVcc-infected Huh-7.5 cells, and its tyrosine 
phosphorylation was evaluated by immunoblotting. 
The p58 form of NS5A was preferentially 
tyrosine-phosphorylated (Fig. 3A). This 
phosphorylation was reduced by knockdown of 
c-Abl (Fig. 3A). In addition, NS5A of the Con1 
isolate was tyrosine-phosphorylated in COS-7 
cells when coexpressed with wild-type (WT), but 
not kinase-dead (KD), c-Abl (Fig. 3B). These 
results suggest that c-Abl is involved in tyrosine 
phosphorylation of NS5A. 
 To identify a putative phosphorylation 
site for c-Abl, tyrosine residues conserved 
between the Con1 (genotype 1b) and JFH1 
(genotype 2a) isolates were mutated to 
phenylalanine in Con1 NS5A. Of the eight 
mutations, the Y334F mutation significantly 
reduced NS5A tyrosine phosphorylation in COS-7 
cells (Fig. 3, C and D). This residue is at the 
carboxy terminus of domain II and corresponds to 
Tyr330 of JFH1 NS5A (Fig. 3E). c-Abl 
phosphorylated NS5A domain II (JFH1) in vitro 
(Fig. 3F). This phosphorylation was reduced by 
the Y330F mutation (Fig. 3F). These results 
suggest that c-Abl phosphorylates NS5A at Tyr330.  
 Tyr330 of NS5A Is Required for Efficient 
HCV Particle Assembly—To examine whether 
Tyr330 of NS5A is required for HCV particle 
assembly, HCV genomic RNAs encoding NS5A 
WT and Y330F (J6/JFH1 WT and Y330F, 
respectively) were transcribed in vitro and 
electroporated into Huh-7.5 cells. As expected, the 
p58 form of NS5A WT was 
tyrosine-phosphorylated (Fig. 4A). The Y330F 
mutation reduced this phosphorylation (Fig. 4A) as 
well as extracellular and intracellular infectivity 
(Fig. 4, B and C). Although the Y330F mutation 
also slightly reduced intracellular HCV (J6/JFH1) 
RNA levels (Fig. 4D) and NS5A expression (Fig. 
4, A and E), the same mutation did not 
significantly affect the replication of the JFH1 
subgenomic replicon (SGR-JFH1) (Fig. 4, F and 
G). These results suggest that Tyr330 of NS5A is 
required for efficient HCV particle assembly.  
 c-Abl Is Dispensable for the Binding of 
Core to Viral RNA—NS5A has been proposed to 
transport viral RNA from replication complexes to 
LD-resident core, thereby promoting nucleocapsid 
formation (6, 7). We examined whether tyrosine 
phosphorylation by c-Abl regulates the subcellular 
localization of NS5A. The association of NS5A 
with LDs was comparable between control and 
c-Abl knockdown cells (Fig. 5, A and B) and was 
unaffected by the Y330F mutation (Fig. 5, C and 
D). We next examined whether c-Abl is required 
for the binding of core to viral RNA. Core was 
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immunoprecipitated from lysates of control and 
c-Abl knockdown cells, and coprecipitated viral 
RNA was quantified by real-time PCR. 
Knockdown of c-Abl slightly increased the 
amount of coprecipitated viral RNA (Fig. 6A), 
while reducing the amount of viral RNA in culture 
supernatants (Fig. 6B). These results suggest that 
c-Abl is dispensable for the binding of core to 
viral RNA.  
 
DISCUSSION 
  NS5A has long been known to exist in 
basally phosphorylated (p56) and 
hyperphosphorylated (p58) forms (17, 18). 
Although the functional difference between these 
two forms is unclear, recent studies have 
implicated the p58 form of NS5A in HCV particle 
assembly (23, 25). Consistent with these studies, 
our results suggest that c-Abl promotes HCV 
particle assembly by phosphorylating the p58 form 
of NS5A. It is difficult to speculate on the exact 
role for this phosphorylation since the mechanism 
by which NS5A facilitates particle assembly 
remains elusive. Because of its RNA-binding 
activity, NS5A has been proposed to transport 
viral RNA to LD-resident core prior to 
nucleocapsid formation (6, 7). However, our 
results suggest that phosphorylation of NS5A by 
c-Abl is dispensable for the binding of core to 
viral RNA. Rather, the amount of core-bound viral 
RNA was increased in c-Abl knockdown cells (Fig. 
6A). This result can be interpreted to mean that 
knockdown of c-Abl impairs a later step in particle 
assembly (i.e., nucleocapsid formation or 
envelopment), thereby preventing core-bound viral 
RNA from being released as virus particles.  
 Tyr330 of NS5A (Tyr2306 in polyprotein 
numbering) is conserved among all genotypes of 
HCV (13) and conforms to the preferred c-Abl 
substrate sequence YXXP (44). We identified this 
tyrosine residue as a putative phosphorylation site 
for c-Abl by coexpressing NS5A mutants with 
c-Abl in COS-7 cells and by in vitro kinase assay. 
Although these systems do not fully represent the 
situation for NS5A in HCV-infected cells, our 
results using J6/JFH1 also indicate that NS5A 
tyrosine phosphorylation is dependent, at least in 
part, on Tyr330. Tyr330 of NS5A is therefore likely 
to be a direct target of c-Abl in HCV-infected cells. 
The SH2 domains of Crk and Nck are known to 
recognize phosphorylated YXXP sequences (45), 
but do not appear to bind to NS5A in 
HCV-infected cells (data not shown). 
  Recent mass spectrometric analyses of 
NS5A identified multiple serine and threonine but 
not tyrosine phosphorylation sites (21, 22). Given 
that NS5A was purified from subgenomic 
replicon-harboring cells in these analyses, it is 
conceivable that phosphorylation of NS5A at 
Tyr330 may occur only in virus particle-producing 
cells.  
 We showed that the Y330F mutation 
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did not significantly affect SGR-JFH1 replication 
(Fig. 4, F and G). In contrast, a previous study 
showed that the Y330A mutation abolished 
SGR-JFH1 replication (13). This difference may 
indicate that although NS5A Tyr330 
phosphorylation is dispensable for RNA 
replication, the structure of the carboxy terminus 
of domain II influences the efficiency of RNA 
replication. 
 HCV exploits various host kinases to 
complete its life cycle (46). For example, HCV 
RNA replication requires c-Src activity (47). We 
showed that imatinib treatment reduced 
intracellular viral RNA levels by ~20% (Fig. 1C). 
This may be because imatinib weakly inhibits 
c-Src (48) or other kinases involved in HCV RNA 
replication.  
 The identification of c-Abl as a host 
factor for HCV particle assembly may have 
clinical implications. HCV has infected ~3% of 
the world's population and is a major cause of liver 
cirrhosis and hepatocellular carcinoma (49). This 
has prompted the development of numerous 
anti-HCV agents that target viral proteins such as 
the NS3-4A protease and NS5A (50) or host 
proteins such as cyclophilin A (51). Imatinib and 
more potent Abl inhibitors are already in clinical 
use as targeted therapeutic agents for CML (31). 
Although the spread of HCV infection may not 
necessarily require particle assembly (52), our 
results suggest the potential of Abl inhibitors as 
therapeutic agents for HCV infection.  
 c-Abl can contribute to liver 
tumorigenesis when activated by oncogenic 
receptor tyrosine kinases (53). However, it is 
unknown whether c-Abl is activated in 
HCV-induced hepatocellular carcinoma.   
 Serine/threonine phosphorylation of the 
NS5A/NS5 proteins has been found not only in 
HCV but also in other members of the family 
Flaviviridae such as bovine viral diarrhea virus, 
yellow fever virus (54), and dengue virus (55). In 
addition, some of them require Src family kinases 
for the assembly and maturation of virus particles 
(56, 57). It would be interesting to determine 
whether tyrosine phosphorylation of the 
NS5A/NS5 proteins is a conserved feature of the 
family Flaviviridae. 
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FIGURE 1. Treatment with imatinib reduces HCV particle assembly. A-D, Huh-7.5 cells were 
infected with HCVcc (J6/JFH1) and treated with DMSO (vehicle) or imatinib (10 µM) for 72 h. A, 
extracellular and intracellular virus particles were harvested and used to infect naive Huh-7.5 cells. Cells 
were stained for core (green) and nuclei (blue). Scale bar, 200 µm. B, extracellular and intracellular 
infectivity (FFU/ml) was quantified by counting core-positive foci and normalized to control values. Data 
represent the mean ± SD (n=3). *, P < 0.01. C, intracellular HCV RNA levels were quantified by 
real-time PCR and normalized to control values. Data represent the mean ± SD (n=3). *, P < 0.05. D, the 
expression levels of core and NS5A were evaluated by immunoblotting. The intensity ratio of core or 
NS5A to GAPDH was calculated from blots and normalized to the control value. E, Huh-7.5 cells were 
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treated with DMSO or imatinib (10 µM) for 72 h. Cell viability was assessed by trypan blue assay. Data 
represent the mean ± SD (n=3). NS, not significant. 
 
FIGURE 2. Knockdown of c-Abl reduces HCV particle assembly. A-E, Huh-7.5 cells were infected 
with a control or c-Abl shRNA-encoding retrovirus together with a control or Arg shRNA-encoding 
retrovirus. A, the expression levels of c-Abl and Arg were evaluated by immunoblotting. B-E, cells were 
infected with HCVcc (J6/JFH1) and incubated for 48 h. B, extracellular and intracellular virus particles 
were harvested and used to infect naive Huh-7.5 cells. Cells were stained for core (green) and nuclei 
(blue). Scale bar, 200 µm. C, extracellular and intracellular infectivity (FFU/ml) was quantified by 
counting core-positive foci and normalized to control values. Data represent the mean ± SD (n=3). *, P < 
0.01. D, intracellular HCV RNA levels were quantified by real-time PCR and normalized to control 
values. Data represent the mean ± SD (n=3). NS, not significant. E, the level of core expression was 
evaluated by immunoblotting. F, c-Abl and Arg mRNA levels in Huh-7.5 cells were quantified by 
real-time PCR and normalized to c-Abl values. Data represent the mean ± SD (n=3). *, P < 0.01. 
 
FIGURE 3. c-Abl phosphorylates NS5A at Tyr330. A, Huh-7.5 cells were infected with a control or 
c-Abl shRNA-encoding retrovirus. Cells were infected with HCVcc (J6/JFH1) and incubated for 96 h. 
Cells were lysed and subjected to immunoprecipitation with anti-NS5A antibody. The level of 
phosphorylated NS5A was evaluated by anti-phosphotyrosine (p-Tyr) immunoblotting. Black arrowheads 
indicate the positions of NS5A. B, COS-7 cells were transfected with a Myc-tagged NS5A (Con1) 
expression vector together with a c-Abl wild-type (WT) or kinase-dead (KD) expression vector. Cells 
were lysed and subjected to immunoprecipitation with anti-Myc antibody. The level of phosphorylated 
NS5A was evaluated by anti-p-Tyr immunoblotting. C, COS-7 cells were transfected with a c-Abl 
expression vector together with a Myc-tagged NS5A expression vector or expression vectors for the 
indicated mutants. The level of NS5A tyrosine phosphorylation was evaluated as in B. D, the intensity 
ratio of p-Tyr to Myc was calculated from blots in C for each mutant and normalized to control values. 
Data represent the mean ± SD (n=3). *, P < 0.01. E, domain structure of NS5A. Numbers indicate amino 
acid positions on the sequence of JFH1 NS5A. Sequences of the carboxy terminus of domain II (the JFH1 
and Con1 isolates) are shown below. AH, amphipathic helix. F, Flag-tagged c-Abl was transiently 
expressed in HEK293T cells and immunoprecipitated with anti-Flag antibody. Immunoprecipitates were 
incubated with GST-tagged NS5A domain II (JFH1) WT or Y330F in kinase buffer. The level of 
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phosphorylated NS5A was evaluated by anti-p-Tyr immunoblotting. 
 
FIGURE 4. The NS5A Y330F mutation reduces HCV particle assembly. A-E, Huh-7.5 cells were 
electroporated with HCV genomic RNAs encoding NS5A WT and Y330F (J6/JFH1 WT and Y330F, 
respectively) and incubated for 48 h. A, cells were lysed and subjected to immunoprecipitation with 
anti-NS5A antibody. The level of phosphorylated NS5A was evaluated by anti-phosphotyrosine (p-Tyr) 
immunoblotting. Black arrowheads indicate the positions of NS5A. B, extracellular and intracellular virus 
particles were harvested and used to infect naive Huh-7.5 cells. Cells were stained for core (green) and 
nuclei (blue). Scale bar, 200 µm. C, extracellular and intracellular infectivity (FFU/ml) was quantified by 
counting core-positive foci and normalized to control values. Data represent the mean ± SD (n=3). *, P < 
0.01. D, intracellular HCV RNA levels were quantified by real-time PCR and normalized to control 
values. Data represent the mean ± SD (n=3). *, P < 0.01. E, the level of NS5A expression was evaluated 
by immunoblotting. F and G, Huh-7.5 cells were electroporated with HCV subgenomic replicon RNAs 
encoding NS5A WT and Y330F (SGR-JFH1 WT and Y330F, respectively) and incubated for 48 h. F, 
intracellular HCV RNA levels were quantified as in D. NS, not significant. G, the level of NS5A 
expression was evaluated by immunoblotting. 
 
FIGURE 5. Knockdown of c-Abl does not affect the association of NS5A with LDs. A and B, Huh-7.5 
cells were infected with a control or c-Abl shRNA-encoding retrovirus. Cells were infected with HCVcc 
(J6/JFH1) and incubated for 48 h. A, cells were stained for NS5A (red), LDs (green), and nuclei (blue). 
Boxed regions are shown enlarged in right panels. Scale Bar, 10 µm. B, the percentage of LDs associated 
with NS5A in each cell was calculated. Data represent the mean ± SD. Fifteen cells were analyzed. NS, 
not significant. C and D, Huh-7.5 cells were electroporated with HCV genomic RNAs encoding NS5A 
WT and Y330F (J6/JFH1 WT and Y330F, respectively) and incubated for 48 h. The subcellular 
localization of NS5A was analyzed as in A and B. 
 
FIGURE 6. Knockdown of c-Abl increases the amount of core-bound viral RNA in HCV-infected 
cells. A and B, Huh-7.5 cells were infected with a control or c-Abl shRNA-encoding retrovirus. Cells 
were infected with HCVcc (J6/JFH1) and incubated for 48 h. A, cells were lysed and subjected to 
immunoprecipitation with anti-core antibody. Coprecipitated viral RNA was quantified by real-time PCR 
and normalized to control values. Data represent the mean ± SD (n=3). *, P < 0.05. The level of 
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immunoprecipitated core was evaluated by immunoblotting. B, HCV RNA levels in culture supernatants 
were quantified by real-time PCR and normalized to control values. Data represent the mean ± SD (n=3). 
*, P < 0.05. 
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